Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 HKD | +1.21% | +11.50% | -7.85% |
26/04 | CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S | CI |
24/04 | CSPC Pharmaceutical's EBT Buys 8.5 Million Shares | MT |
Business Summary
- drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%);
- vitamin C (10.1%);
- antibiotics (6.2%);
- other (5%): including anhydrous and raw caffeine.
Net sales are distributed geographically as follows: China (82.8%), Asia (7.2%), Europe (4.6%), the Americas (4.4%) and others (1%).
Number of employees: 23,500
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Finished Drugs
81.5
%
| 24,520 | 79.3 % | 28,329 | 81.5 % | +15.53% |
Functional Food and Others
6.9
%
| 1,966 | 6.4 % | 2,400 | 6.9 % | +22.06% |
Bulk Products - Vitamin C
6.1
%
| 2,529 | 8.2 % | 2,132 | 6.1 % | -15.70% |
Bulk Products - Antibiotics
5.4
%
| 1,922 | 6.2 % | 1,892 | 5.4 % | -1.57% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
86.4
%
| 26,139 | 84.5 % | 30,038 | 86.4 % | +14.91% |
Other Asian Regions
5.0
%
| 1,736 | 5.6 % | 1,749 | 5.0 % | +0.77% |
Europe
4.1
%
| 1,268 | 4.1 % | 1,411 | 4.1 % | +11.27% |
North America
2.8
%
| - | - | 974 | 2.8 % | - |
Others
1.7
%
| 284 | 0.9 % | 580 | 1.7 % | +104.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cui Long Zhang
CEO | Chief Executive Officer | 55 | 01/96/01 |
Dong Chen Cai
CHM | Chairman | 70 | 01/98/01 |
Hao Jiang
BRD | Director/Board Member | 41 | 01/20/01 |
Zhen Guo Wang
BRD | Director/Board Member | 54 | 20/12/20 |
Huai Yu Wang
BRD | Director/Board Member | 61 | 01/10/01 |
Wei Dong Pan
BRD | Director/Board Member | 55 | 01/06/01 |
Jin Xu Wang
PRN | Corporate Officer/Principal | 53 | 10/13/10 |
Tai On Lo
SEC | Corporate Secretary | 69 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dong Chen Cai
CHM | Chairman | 70 | 01/98/01 |
Huai Yu Wang
BRD | Director/Board Member | 61 | 01/10/01 |
Kin Man Chak
BRD | Director/Board Member | 58 | 01/05/01 |
Chun Kwok Au
BRD | Director/Board Member | 51 | 27/21/27 |
Jin Xu Wang
PRN | Corporate Officer/Principal | 53 | 10/13/10 |
Chuan Chen
BRD | Director/Board Member | 61 | 06/16/06 |
Chun Lei Li
BRD | Director/Board Member | - | 12/17/12 |
Qingxi Wang
BRD | Director/Board Member | 58 | 20/18/20 |
Quan Li
BRD | Director/Board Member | 45 | 08/22/08 |
Hong Guang Wang
BRD | Director/Board Member | 62 | 27/21/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,922,719,732 | 8,371,200,069 ( 70.21 %) | 0 | 70.21 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
131,267,092 | 69.84% | 672,004,813 $ | |
51,241,785 | 46.32% | 51,723,458 $ |
Company contact information
CSPC Pharmaceutical Group Ltd.
No. 226 Huanghe Street
050035, Shijiazhuang
+86 31 1870 37015
http://www.cspc.com.hkSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.85% | 9.99B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 1093 Stock
- Company CSPC Pharmaceutical Group Ltd.